In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose We evaluated the usefulness of the in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) for prediction of clinical response to fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer. Materials and Methods Tumor specimens of 86 patients with pathologically confirmed stage II colorectal adenocarcinoma were tested for chemosensitivity to fluorouracil. Chemosensitivity was determined by cell death rate (CDR) of drug-exposed cells, calculated by comparing the intracellular ATP level with that of untreated controls. Results Among the 86 enrolled patients who underwent radical surgery followed by fluorouracilbased adjuvant chemotherapy, recurrence was found in 11 patients (12.7%). The CDR ! 20% group was associated with better disease-free survival than the CDR < 20% group (89.4% vs. 70.1%, p=0.027). Multivariate analysis showed that CDR < 20% and T4 stage were poor prognostic factors for disease-free survival after fluorouracil-based adjuvant chemotherapy. Conclusion In stage II colorectal cancer, the in vitro ATP-CRA may be useful in identifying patients likely to benefit from fluorouracil-based adjuvant chemotherapy.
Abstract
Purpose We evaluated the usefulness of the in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) for prediction of clinical response to fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer. Materials and Methods Tumor specimens of 86 patients with pathologically confirmed stage II colorectal adenocarcinoma were tested for chemosensitivity to fluorouracil. Chemosensitivity was determined by cell death rate (CDR) of drug-exposed cells, calculated by comparing the intracellular ATP level with that of untreated controls. Results Among the 86 enrolled patients who underwent radical surgery followed by fluorouracilbased adjuvant chemotherapy, recurrence was found in 11 patients (12.7%). The CDR ! 20% group was associated with better disease-free survival than the CDR < 20% group (89.4% vs. 70.1%, p=0.027). Multivariate analysis showed that CDR < 20% and T4 stage were poor prognostic factors for disease-free survival after fluorouracil-based adjuvant chemotherapy. Conclusion In stage II colorectal cancer, the in vitro ATP-CRA may be useful in identifying patients likely to benefit from fluorouracil-based adjuvant chemotherapy.
참고문헌 (25)
- Hamburger AW, "Primary bioassay of human tumor stem cells", Science, 197, pp.461~463 (1977)
- Rozencweig M, "In vitro growth of human malignancies in a cloning assay", Recent Results Cancer Res, 94, pp.1~7 (1984)
- Yamaue H, "Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay", Eur J Cancer, 27, pp.1258~1263 (1991)
- Vescio RA, "In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture", Proc Natl Acad Sci U S A, 84, pp.5029~5033 (1987)
- Shin Myung Kang, "A Feasibility Study of Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA) as a Chemosensitivity Test for Lung Cancer", Cancer Research and Treatment, 37(4), pp.223~227 (2005), 대한암학회
- Cree IA, "Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity", Anticancer Drugs, 7, pp.630~635 (1996)
- Konecny G, "Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer", Gynecol Oncol, 77, pp.258~263 (2000)
- 허정욱, "Heterogeneity of Adenosine Triphosphate-Based Chemotherapy Response Assay in Colorectal Cancer - Secondary Publication", Yonsei Medical Journal, 50(5), pp.697~703 (2009), 연세대학교의과대학
- Hur H, "Adenosine triphosphate-based chemotherapy response assayguided chemotherapy in unresectable colorectal liver metas-tasis", Br J Cancer, 106, pp.53~60 (2012)
- Seulkee Park, "In Vitro Adenosine Triphosphate Based Chemotherapy Response Assay in Gastric Cancer", Journal of Gastric Cancer, 10(4), pp.155~161 (2010), 대한위암학회
- Benson AB 3rd, "American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer", J Clin Oncol, 22, pp.3408~3419 (2004)
- Schippinger W, "A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer", Br J Cancer, 97, pp.1021~1027 (2007)
- Compton CC, "Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999", Arch Pathol Lab Med, 124, pp.979~994 (2000)
- Andre T, "Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial", J Clin Oncol, 27, pp.3109~3116 (2009)
- Quasar Collaborative Group, "Adjuvant chemotherapy versus observation in patients with colorectal cancer : a randomised study", Lancet, 370, pp.2020~2029 (2007)
- Gill S, "Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer : who benefits and by how much?", J Clin Oncol, 22, pp.1797~1806 (2004)
- Markowitz SD, "Molecular origins of cancer : molecular basis of colorectal cancer", N Engl J Med, 361, pp.2449~2460 (2009)
- Bertagnolli MM, "Microsatellite instability and loss of heterozygosity at chromosomal location 18q : prospective evaluation of biomarkers for stages II and III colon cancer : a study of CALGB 9581 and 89803", J Clin Oncol, 29, pp.3153~3162 (2011)
- Roth AD, "Prognostic role of KRAS and BRAF in stage II and III resected colon cancer : results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial", J Clin Oncol, 28, pp.466~474 (2010)
- Salazar R, "Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer", J Clin Oncol, 29, pp.17~24 (2011)
- Maak M, "Independent validation of a prognostic genomic signature(ColoPrint)for patients with stage II colon cancer", Ann Surg, 257, pp.1053~1058 (2013)
- Kim HA, "The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer", Breast, 17, pp.19~26 (2008)
- 이지현, "Predictive Value of In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay in Advanced Gastric Cancer Patients Who Received Oral 5-Fluorouracil after Curative Resection", Cancer Research and Treatment, 43(2), pp.117~123 (2011), 대한암학회
- Meyers M, "Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses", Cancer Res, 61, pp.5193~5201 (2001)
- Ribic CM, "Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer", N Engl J Med, 349, pp.247~257 (2003)